Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | MAP3K7 | O43318 | 5/20 | 0.65 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.65 |
| ▸ | FLT3 | P36888 | 1/20 | 0.63 |
| ▸ | BLK | P51451 | 1/20 | 0.63 |
| ▸ | JAK3 | P52333 | 5/20 | 0.62 |
| ▸ | JAK2 | O60674 | 3/20 | 0.62 |
| ▸ | JAK1 | P23458 | 2/20 | 0.62 |
| ▸ | TYK2 | P29597 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.60 |
| ▸ | SRC | P12931 | 1/20 | 0.60 |
| ▸ | BTK | Q06187 | 2/20 | 0.59 |
| ▸ | BRD4 | O60885 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10127802 | 0.93 | EGFR (0.87) | EGFRMAP3K7MAP2K1FLT3BLK | |
| SCHEMBL17059685 | 0.87 | EGFR (1.00) | EGFRFLT3BLKJAK3JAK2 | |
| SCHEMBL13169820 | 0.85 | EGFR (0.63) | EGFRL3MBTL1MAP3K7MAP2K1FLT3 | |
| SCHEMBL10155231 | 0.85 | L3MBTL1 (0.89) | EGFRL3MBTL1MAP3K7MAP2K1FLT3 | |
| SCHEMBL28980990 | 0.83 | SRC (0.69) | EGFRMAP3K7MAP2K1FLT3BLK | |
| SCHEMBL28980965 | 0.83 | MAP3K7 (0.81) | EGFRMAP3K7MAP2K1FLT3BLK | |
| SCHEMBL10361955 | 0.82 | JAK3 (0.61) | EGFRMAP3K7MAP2K1FLT3BLK | |
| SCHEMBL28980992 | 0.82 | BRD4 (0.72) | EGFRL3MBTL1MAP3K7MAP2K1FLT3 | |
| SCHEMBL28980985 | 0.81 | MAP3K7 (0.71) | EGFRMAP3K7MAP2K1FLT3BLK | |
| SCHEMBL10127782 | 0.80 | MAP3K7 (0.75) | EGFRMAP3K7MAP2K1FLT3BLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190040065-A1 | EGFR Inhibitors and Methods of Treating Disorders | DANA-FARBER CANCER INSTITUTE, INC. | 2019-02-07 | — | — | US | disclosed |
| US-9908884-B2 | EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | EGFR, ERBB2, ERBB4 | EGFR 1/4885L3MBTL1 4418/4885MAP3K7 121/4885 |
| US-20190040065-A1 | EGFR Inhibitors and Methods of Treating Disorders | EGFR, ERBB2, ERBB4 | EGFR 1/4885L3MBTL1 4418/4885MAP3K7 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.